Related references
Note: Only part of the references are listed.Antitumor Activity of Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor, in ETV6-NTRK3-Positive Acute Myeloid Leukemia
Kristen M. Smith et al.
MOLECULAR CANCER THERAPEUTICS (2018)
De novo and secondary anaplastic meningiomas: a study of clinical and histomolecular prognostic factors
Matthieu Peyre et al.
NEURO-ONCOLOGY (2018)
Loss of histone H3K27me3 identifies a subset of meningiomas with increased risk of recurrence
Leah M. Katz et al.
ACTA NEUROPATHOLOGICA (2018)
Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas
Ganesh M. Shankar et al.
NEURO-ONCOLOGY (2017)
Non-myogenic tumors display altered expression of dystrophin (DMD) and a high frequency of genetic alterations
Leonela N. Luce et al.
ONCOTARGET (2017)
Targeted sequencing of SMO and AKT1 in anterior skull base meningiomas
Matthew R. Strickland et al.
JOURNAL OF NEUROSURGERY (2017)
DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis
Felix Sahm et al.
LANCET ONCOLOGY (2017)
Pan-cancer analysis of homozygous deletions in primary tumours uncovers rare tumour suppressors
Jiqiu Cheng et al.
NATURE COMMUNICATIONS (2017)
Integrated genomic analyses of de novo pathways underlying atypical meningiomas
Akdes Serin Harmanci et al.
NATURE COMMUNICATIONS (2017)
Intratumoral heterogeneity and TERT promoter mutations in progressive/higher-grade meningiomas
Tareq A. Juratli et al.
ONCOTARGET (2017)
Genomic landscape of high-grade meningiomas
Wenya Linda Bi et al.
NPJ GENOMIC MEDICINE (2017)
In-depth Genetic Analysis of Sclerosing Epithelioid Fibrosarcoma Reveals Recurrent Genomic Alterations and Potential Treatment Targets
Elsa Arbajian et al.
CLINICAL CANCER RESEARCH (2017)
GATK CNV: copy-number variation discovery from coverage data
Mehrtash Babadi et al.
CANCER RESEARCH (2017)
TERT Promoter Mutations and Risk of Recurrence in Meningioma
Felix Sahm et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
TERT Promoter Mutations and Risk of Recurrence in Meningioma
Felix Sahm et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Sambamba: fast processing of NGS alignment formats
Artem Tarasov et al.
BIOINFORMATICS (2015)
Cell cycle and dystrophin dysregulation in GIST
Yuexiang Wang et al.
CELL CYCLE (2015)
Oncotator: Cancer Variant Annotation Tool
Alex H. Ramos et al.
HUMAN MUTATION (2015)
The H3K27me3 demethylase UTX is a gender-specific tumor suppressor in T-cell acute lymphoblastic leukemia
Joni Van der Meulen et al.
BLOOD (2015)
featureCounts: an efficient general purpose program for assigning sequence reads to genomic features
Yang Liao et al.
BIOINFORMATICS (2014)
High Incidence of Activating TERT Promoter Mutations in Meningiomas Undergoing Malignant Progression
Stephane Goutagny et al.
BRAIN PATHOLOGY (2014)
Dystrophin is a tumor suppressor in human cancers with myogenic programs
Yuexiang Wang et al.
NATURE GENETICS (2014)
Anchored multiplex FOR for targeted next-generation sequencing
Zongli Zheng et al.
NATURE MEDICINE (2014)
Secretory meningiomas are defined by combined KLF4 K409Q and TRAF7 mutations
David E. Reuss et al.
ACTA NEUROPATHOLOGICA (2013)
Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system
Christian Koelsche et al.
ACTA NEUROPATHOLOGICA (2013)
STAR: ultrafast universal RNA-seq aligner
Alexander Dobin et al.
BIOINFORMATICS (2013)
Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples
Kristian Cibulskis et al.
NATURE BIOTECHNOLOGY (2013)
Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations
Priscilla K. Brastianos et al.
NATURE GENETICS (2013)
Genomic Analysis of Non-NF2 Meningiomas Reveals Mutations in TRAF7, KLF4, AKT1, and SMO
Victoria E. Clark et al.
SCIENCE (2013)
Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs
Christopher T. Saunders et al.
BIOINFORMATICS (2012)
The role of chemotherapy and targeted therapy in the treatment of intracranial meningioma
Marc C. Chamberlain
CURRENT OPINION IN ONCOLOGY (2012)
Regulation of mTOR Complex 2 Signaling in Neurofibromatosis 2-Deficient Target Cell Types
Marianne F. James et al.
MOLECULAR CANCER RESEARCH (2012)
Novel mutations target distinct subgroups of medulloblastoma
Giles Robinson et al.
NATURE (2012)
Absolute quantification of somatic DNA alterations in human cancer
Scott L. Carter et al.
NATURE BIOTECHNOLOGY (2012)
Quantification of dystrophin immunofluorescence in dystrophinopathy muscle specimens
L. E. Taylor et al.
NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY (2012)
ContEst: estimating cross-contamination of human samples in next-generation sequencing data
Kristian Cibulskis et al.
BIOINFORMATICS (2011)
Anatomic Location Is a Risk Factor for Atypical and Malignant Meningiomas
Ari J. Kane et al.
CANCER (2011)
Mutational Inactivation of STAG2 Causes Aneuploidy in Human Cancer
David A. Solomon et al.
SCIENCE (2011)
A scalable, fully automated process for construction of sequence-ready human exome targeted capture libraries
Sheila Fisher et al.
GENOME BIOLOGY (2011)
Detecting simultaneous changepoints in multiple sequences
Nancy R. Zhang et al.
BIOMETRIKA (2010)
Genomic Profiling Reveals Alternative Genetic Pathways of Meningioma Malignant Progression Dependent on the Underlying NF2 Status
Stephane Goutagny et al.
CLINICAL CANCER RESEARCH (2010)
The landscape of somatic copy-number alteration across human cancers
Rameen Beroukhim et al.
NATURE (2010)
Mutational Spectrum of DMD Mutations in Dystrophinopathy Patients: Application of Modern Diagnostic Techniques to a Large Cohort
Kevin M. Flanigan et al.
HUMAN MUTATION (2009)
Dystrophin is a microtubule-associated protein
Kurt W. Prins et al.
JOURNAL OF CELL BIOLOGY (2009)
Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing
Andreas Gnirke et al.
NATURE BIOTECHNOLOGY (2009)
Is there an association between meningioma and hormone replacement therapy?
Svetlana Blitshteyn et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Dystrophin-deficient mdx mice display a reduced life span and are susceptible to spontaneous rhabdomyosarcoma
Jeffrey S. Chamberlain et al.
FASEB JOURNAL (2007)
Dystrophin, its interactions with other proteins, and implications for muscular dystrophy
James M. Ervasti
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2007)
Digital karyotyping reveals frequent inactivation of the Dystrophin/DMD gene in malignant melanoma
Henrike Koerner et al.
CELL CYCLE (2007)
DMD and IL1RAPL1: two large adjacent genes localized within a common fragile site (FRAXC) have reduced expression in cultured brain tumors
S. McAvoy et al.
CYTOGENETIC AND GENOME RESEARCH (2007)
Risk of brain tumors associated with exposure to exogenous female sex hormones
Annette Wigertz et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2006)
Copy number variation in the genome; the human DMD gene as an example
S. J. White et al.
CYTOGENETIC AND GENOME RESEARCH (2006)
Deletion and duplication screening in the DMD gene using MLPA
T Lalic et al.
EUROPEAN JOURNAL OF HUMAN GENETICS (2005)
NF2 deficiency promotes tumorigenesis and metastasis by destabilizing adherens junctions
D Lallemand et al.
GENES & DEVELOPMENT (2003)
Alterations of the tumor suppressor genes CDKN2A (p16INK4a), p14ARF, CDKN2B (p15INK4b), and CDKN2C (p18INK4c) in atypical and anaplastic meningiomas
J Boström et al.
AMERICAN JOURNAL OF PATHOLOGY (2001)